Adial Pharmaceuticals, Inc.

NASDAQ (USD): Adial Pharmaceuticals, Inc. (ADIL)

Last Price

1.07

Today's Change

+0.02 (1.90%)

Day's Change

1.00 - 1.07

Trading Volume

126,110

Profile
ADIL

Exchange:  NASDAQ Capital Market NASDAQ Capital Market

Currency:  USD USD

Sector:  Healthcare - Healthcare Healthcare - Healthcare

Industry: 

CEO:  Mr. Cary John Claiborne MBA Mr. Cary John Claiborne MBA

Full Time Employees:  4 4

IPO Date:  2018-07-27 2018-07-27

CIK:  0001513525 0001513525

ISIN:  US00688A2050 US00688A2050

CUSIP:  00688A106 00688A106

Beta:  1.30 1.30

Last Dividend:  0.00 0.00

Dcf Diff:  -0.91 -0.91

Dcf:  1.98 1.98

Description

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

Address

1180 Seminole Trail,
Charlottesville, VA 22901, US

434 422 9800

http://www.adialpharma.com

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment